{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:28:46Z","timestamp":1774970926878,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clgc.2024.102256","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T06:51:30Z","timestamp":1730443890000},"page":"102256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of Renin-Angiotensin System Inhibitors on Response to PD1\/L1 Inhibitors in Patients With Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4564-4304","authenticated-orcid":false,"given":"Kathryn","family":"Fortune","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-6906","authenticated-orcid":false,"given":"Soham","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5853-9697","authenticated-orcid":false,"given":"Jack","family":"Masur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0834-8688","authenticated-orcid":false,"given":"Paul","family":"Viscuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7502-1584","authenticated-orcid":false,"given":"Michael","family":"Devitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Dreicer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-8178","authenticated-orcid":false,"suffix":"IV","given":"William Paul","family":"Skelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2024.102256_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0391560318802166","article-title":"Systemic therapy of metastatic renal cell carcinoma: review of the current literature","volume":"86","author":"Zerdes","year":"2019","journal-title":"Urologia"},{"issue":"1","key":"10.1016\/j.clgc.2024.102256_bib0002","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/life12010024","article-title":"Immunotherapy and metastatic renal cell carcinoma: a review of new treatment Approaches","volume":"12","author":"Kathuria-Prakash","year":"2021","journal-title":"Life"},{"issue":"3","key":"10.1016\/j.clgc.2024.102256_bib0003","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/OP.21.00419","article-title":"Clinical review on the management of metastatic renal cell carcinoma","volume":"18","author":"Tran","year":"2022","journal-title":"JCO Oncol Practice"},{"issue":"7","key":"10.1016\/j.clgc.2024.102256_bib0004","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11934-023-01160-x","article-title":"Role of the Renin\u2013angiotensin system components in renal cell carcinoma: a literature review","volume":"24","author":"Mour\u00e3o","year":"2023","journal-title":"Curr Urol Rep"},{"issue":"1","key":"10.1016\/j.clgc.2024.102256_bib0005","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat Commun"},{"issue":"410","key":"10.1016\/j.clgc.2024.102256_bib0006","doi-asserted-by":"crossref","first-page":"eaan5616","DOI":"10.1126\/scitranslmed.aan5616","article-title":"Targeting the renin-angiotensin system to improve cancer treatment: implications for immunotherapy","volume":"9","author":"Pinter","year":"2017","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.clgc.2024.102256_bib0007","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.clgc.2021.04.002","article-title":"Angiotensin blockade modulates the activity of PD1\/L1 inhibitors in metastatic urothelial carcinoma","volume":"19","author":"Jain","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2024.102256_bib0008","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.clgc.2022.04.012","article-title":"Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors","volume":"20","author":"Nuzzo","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2024.102256_bib0009","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1200\/JCO.2020.38.6_suppl.473","article-title":"Any regression of tumor (ART) within 12 weeks versus RECIST 1.1 response category as an intermediate endpoint to assess the activity of immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (MUC)","volume":"38","author":"Curran","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102256_bib0010","doi-asserted-by":"crossref","first-page":"S591","DOI":"10.1016\/j.annonc.2022.07.148","article-title":"116P any regression of tumor (ART) as an intermediate endpoint in patients (Pts) treated with immune checkpoint inhibitors (ICI): a pan-cancer analysis","volume":"33","author":"El Zarif","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102256_bib0011","doi-asserted-by":"crossref","first-page":"R205","DOI":"10.1152\/ajpregu.00544.2012","article-title":"Angiotensin-converting enzyme and the tumor microenvironment: mechanisms beyond angiogenesis","volume":"305","author":"Okwan-Duodu","year":"2013","journal-title":"Am J Physiol Regulat Integrat Comparative Physiol"},{"key":"10.1016\/j.clgc.2024.102256_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1061394","article-title":"TGF-\u03b2: a novel predictor and target for anti-PD-1\/PD-L1 therapy","volume":"13","author":"Yi","year":"2022","journal-title":"Front Immunol"},{"issue":"7693","key":"10.1016\/j.clgc.2024.102256_bib0013","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.clgc.2024.102256_bib0014","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12885-022-09200-4","article-title":"Angiotensin blockade therapy and survival in pancreatic cancer: a population study","volume":"22","author":"Keith","year":"2022","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2024.102256_bib0015","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.21873\/anticanres.14980","article-title":"Impact of Renin\u2013angiotensin system inhibitors on the efficacy of anti-PD-1\/PD-L1 antibodies in NSCLC patients","volume":"41","author":"Tozuka","year":"2021","journal-title":"Anticancer Res"},{"issue":"11","key":"10.1016\/j.clgc.2024.102256_bib0016","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732400226X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732400226X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T15:19:38Z","timestamp":1753111178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732400226X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S155876732400226X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102256","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Renin-Angiotensin System Inhibitors on Response to PD1\/L1 Inhibitors in Patients With Metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102256"}}